Oxford, UK: 29 November 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that it has been presented with the techMARK 2007 Achievement of the Year award for its collaboration with sanofi-aventis. The techMARK Awards, organised by the London Stock Exchange, are designed to reward outstanding achievement in the technology market. Professor Alan Kingsman, Oxford BioMedica’s Chief Executive Officer, collected the award last night during the ceremony held at the InterContinental Hotel in London.

Oxford BioMedica announced its collaboration with sanofi-aventis in March 2007 for the global development and commercialisation of TroVax®, its novel immunotherapy, for the treatment and prevention of cancers. Under the terms of this agreement, sanofi-aventis will pay Oxford BioMedica up to €518 million if all development and registration targets are met for certain defined indications. Additional payments will be made if regulatory milestones are achieved in other cancer types. Oxford BioMedica is also entitled to escalating royalties on global sales of TroVax and to further undisclosed commercial milestones when net sales of TroVax reach certain levels.

Professor Kingsman commented: "The sanofi-aventis deal was a transformational event for Oxford BioMedica that provides both near and long-term value as well as clear endorsement of our most advanced product. I am honoured to receive this prestigious award. It is a testament to the achievement of the entire team at Oxford BioMedica.”

-Ends-

For further information, please contact:

Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive
Tel: +44 (0)1865 783 000

JPMorgan Cazenove Limited:
James Mitford/ Gina Gibson
Tel: +44 (0)20 7588 2828

City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson
Buchanan Communications
Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:
Gemma Price/ Holly Griffiths/ Katja Stout
College Hill
Tel: +44 (0)20 7457 2020

Notes to editors

1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of novel therapeutic vaccines and gene-based therapies with a focus on oncology and neurotherapy. The Company was established in 1995 as a spin-out from Oxford University, and is listed on the London Stock Exchange.

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. In oncology, the lead product candidate is TroVax®, an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. A Phase III trial of TroVax in renal cancer is ongoing and two Phase III trials in colorectal cancer are planned. Oxford BioMedica has two other anti-cancer product candidates in Phase II development for melanoma and pancreatic cancer respectively. In neurotherapy, the Company has submitted a Clinical Trial Application to start a Phase I/II trial of its gene-based treatment for Parkinson’s disease, ProSavin®. The neurotherapy pipeline also includes preclinical gene-based therapeutics for vision loss, motor neuron disease and nerve repair.

The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 80 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Corporate partners include sanofi-aventis for TroVax and Wyeth for an anti-cancer targeted antibody therapy. The Company also has collaborations with Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk

2. techMARK Awards
The annual techMARK Awards ceremony and dinner, hosted by the London Stock Exchange and sponsored by PricewaterhouseCoopers, is one of the largest gatherings of technology companies in the UK. It is the event to attend for anybody involved in the UK technology and life sciences markets.